Company Analysis
Sign in

Oculis Holding AG (OCS)

Nasdaq: OCS · Pharmaceutical Preparations · Zug, CH · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.1
◀ Past 4.7● Present 5.3▶ Future 5.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

14 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Oculis Holding AG’s names, not what it holds today.

Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
7
Against 4 in 2024 and none in 2023
Applications published
24
10 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
'07'11'12'13'14'15'16'18'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals11
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Oculis Operations Sàrl a subsidiary
CH, as the owner printed on each patent
11 granted
17 published
Oculis EHF a subsidiary
IS, as the owner printed on each patent
3 granted
4 published
OCULIS EHF a subsidiary
named as the applicant on its applications, in IS
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,403,148PH stabilized ophthalmic compositionsPharmaceuticalsOculis Operations Sàrl
Sep 2, 202512,403,147Treatment of ocular inflammation following ocular surgeryPharmaceuticalsOculis Operations Sàrl
Aug 26, 202512,397,002PH stabilized ophthalmic dexamethasone compositionsPharmaceuticalsOculis Operations Sàrl
Aug 26, 202512,397,001Treatment of ocular inflammation with ophthalmic compositionsPharmaceuticalsOculis Operations Sàrl
Aug 26, 202512,397,000Stabilized ophthalmic dexamethasone compositionsPharmaceuticalsOculis Operations Sàrl
Aug 12, 202512,383,565Treatment of diabetic retinopathy with ophthalmic compositionsPharmaceuticalsOculis Operations Sàrl
Feb 25, 202512,233,133Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient deliveryPharmaceuticalsOculis Operations Sàrl
Sep 24, 202412,097,209Diabetic retinopathy treatment with stabilized dexamethasonePharmaceuticalsOculis Operations Sàrl
Sep 17, 202412,090,162Treatment of diabetic retinopathyPharmaceuticalsOculis Operations Sàrl
Sep 17, 202412,090,161Treatment of ocular inflammationPharmaceuticalsOculis Operations Sàrl
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387411PH STABILIZED OPHTHALMIC COMPOSITIONSPharmaceuticalsOculis Operations Sàrl
Oct 9, 20252025/0313529SYNTHESIS OF SMALL MOLECULE AGONISTS OF NEUROPTROPHINOrganic fine chemistryOculis Operations Sàrl
Jun 5, 20252025/0177561PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERYPharmaceuticalsOculis Operations Sàrl
Apr 17, 20252025/0120985METHOD OF TREATING DIABETIC MACULAR EDEMAPharmaceuticalsOculis Operations Sàrl
Jan 9, 20252025/0009762PH STABILIZED OPHTHALMIC COMPOSITIONSPharmaceuticalsOculis Operations Sàrl · patent 12,403,148 granted from it
Jan 9, 20252025/0009761PH STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSPharmaceuticalsOculis Operations Sàrl · patent 12,397,002 granted from it
Jan 9, 20252025/0009760TREATMENT OF DIABETIC RETINOPATHY WITH OPHTHALMIC COMPOSITIONSPharmaceuticalsOculis Operations Sàrl · patent 12,383,565 granted from it
Jan 9, 20252025/0009759TREATMENT OF OCULAR INFLAMMATION WITH OPHTHALMIC COMPOSITIONSPharmaceuticalsOculis Operations Sàrl · patent 12,397,001 granted from it
Jan 9, 20252025/0009758STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSPharmaceuticalsOculis Operations Sàrl · patent 12,397,000 granted from it
Jan 9, 20252025/0009757TREATMENT OF OCULAR INFLAMMATION FOLLOWING OCULAR SURGERYPharmaceuticalsOculis Operations Sàrl · patent 12,403,147 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 16 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OCS · research, not advice